Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$65 Mln
P/E Ratio
--
P/B Ratio
0.49
Industry P/E
--
Debt to Equity
0.17
ROE
-0.63 %
ROCE
-53.7 %
Div. Yield
0 %
Book Value
2.08
EPS
-1.33
CFO
$-207.69 Mln
EBITDA
$-281.65 Mln
Net Profit
$-288.71 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Pyxis Oncology Inc (PYXS)
| -30.77 | -10.74 | -30.77 | -76.16 | -28.38 | -- | -- |
|
BSE Sensex*
| 2.14 | 3.92 | 4.44 | 8.38 | 11.80 | 20.19 | 11.16 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Pyxis Oncology Inc (PYXS)
| -13.23 | 34.33 | -87.78 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.78 | 9,808.03 | 20.22 | 23.13 | |
| 290.25 | 8,956.09 | 22.08 | 58.42 | |
| 26.54 | 9,559.25 | -- | -28.77 | |
| 103.22 | 10,030.35 | 30.81 | 14.16 |
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1... (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts. Address: 321 Harrison Avenue, Boston, MA, United States, 02118 Read more
Co-Founder & Independent Chairman
Mr. John L. Flavin M.B.A., MBA, Ph.D.
Co-Founder & Independent Chairman
Mr. John L. Flavin M.B.A., MBA, Ph.D.
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Pyxis Oncology Inc (PYXS) stood at $ 157 Mln as on 31-Dec-24
The share price of Pyxis Oncology Inc (PYXS) is $1.08 (NASDAQ) as of 23-Apr-2025 16:00 EDT. Pyxis Oncology Inc (PYXS) has given a return of -28.38% in the last 3 years.
Pyxis Oncology Inc (PYXS) has a market capitalisation of $ 65 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Pyxis Oncology Inc (PYXS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Pyxis Oncology Inc (PYXS) and enter the required number of quantities and click on buy to purchase the shares of Pyxis Oncology Inc (PYXS).
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts. Address: 321 Harrison Avenue, Boston, MA, United States, 02118
The CEO & director of Mr. John L. Flavin M.B.A., MBA, Ph.D.. is Pyxis Oncology Inc (PYXS), and CFO & Sr. VP is Mr. John L. Flavin M.B.A., MBA, Ph.D..
There is no promoter pledging in Pyxis Oncology Inc (PYXS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Pyxis Oncology Inc (PYXS) | Ratios |
|---|---|
|
Return on equity(%)
|
-62.75
|
|
Operating margin(%)
|
-424.23
|
|
Net Margin(%)
|
-478.95
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Pyxis Oncology Inc (PYXS) was $0 Mln.
$0.06
(
